



SOFT TISSUE SARCOMA PANEL

Next Generation Sequencing (NGS) based genomic profiling.

Single test, Multiple fusions: Reproducible and economical solution to identify fusions in Sarcomas using RNA sequencing.



Common Fusion in Soft Tissue Sarcoma



MedGenome Soft Tissue Sarcoma Panel

Genomic alterations (SNVs, InDels and Fusions) in all NCCN guideline recommended soft tissue sarcoma cancer related genes are screened using NGS. A total of 109 genes are screened out of which 83 are analysed for fusions through RNA sequencing.

Provides accurate diagnosis, prognosis and therapy selection

Known and Unknown fusion partners can be identified through this assay

Identifies actionable/potentially actionable biomarkers

Result interpretation and treatment recommendations are based on AMP-ASCO-CAP guidelines

Comprehensive coverage of complete coding regions of all the genes and intron/exon boundaries

Covers tumour agnostic biomarkers such BRAF, RET, NTRK1, NTRK2 and NTRK3 which have approved targeted therapies across all metastatic solid tumours.

